Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: Impact of HAART

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 692-702

  El Khoury, Petra ^a,b   Ghislain, Mathilde ^c,d   Villard, Elise F ^a,b   Le Goff, Wilfried ^a,b,e   Lascoux Combe, Caroline ^f   Yeni, Patrick ^g   Meyer, Laurence ^c,d,h   Vigouroux, Corinne ^b,e,i   Goujard, Cécile ^c,h,j   Guerin, Maryse ^a,b,e  

^a Sorbonne Universités   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Unite de Gene Tique Me Dicale   (Lebanon)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e BICÊTRE HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h BICHAT HOSPITAL   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j CENTRE DE RECHERCHE SAINT ANTOINE   (France)

more..

Author keywords

Antiretroviral therapy; High density lipoprotein function; Highly active antiretroviral therapy; Human immunodeficiency virus; Macrophage cholesterol efflux; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATAZANAVIR; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; SCAVENGER RECEPTOR BI; TENOFOVIR; ABCA1 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOCHEMISTRY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THP 1 MACROPHAGE; BLOOD; CLINICAL TRIAL; HIV INFECTIONS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TUMOR CELL LINE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATP BINDING CASSETTE TRANSPORTER 1; CELL LINE, TUMOR; CHOLESTEROL; FEMALE; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL3; MACROPHAGES; MALE; MIDDLE AGED;

EID: 84925326066     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M054510     Document Type: Article

References (50)

1. Delaney, J. A., R. Scherzer, M. L. Biggs, M. G. Shliplak, J. F. Polak, J. S. Currier, R. A. Kronmal, C. Wanke, P. Bacchetti, D. O'Leary, et al. 2010. Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS. 24 : 2201-2209.
2. Friis-Møller, N., C. A. Sabin, R. Weber, A. d'Arminio Monforte, W. M. El-Sadr, P. Reiss, R. Thiebaut, L. Morfeldt, S. De Wit, C. Pradier, et al. 2003. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349 : 1993-2003.
3. El-Sadr, W. M., J. Lundgren, J. D. Neaton, F. Gordin, D. Abrams, R. C. Arduino, A. Babiker, W. Burman, N. Clumeck, C. J. Cohen, et al. 2006. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355 : 2283-2296.
4. Boufassa, F., C. Goujard, J. P. Viard, R. Carlier, B. Lefebvre, P. Yeni, O. Bouchaud, J. Capeau, L. Meyer, and C. Vigouroux. 2012. Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir. Ther. 17 : 91-100.
5. De Lorenzo, F., S. Collot-Teixeira, M. Boffito, M. Feher, B. Gazzard, and J. L. McGregor. 2008. Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures. Curr. Med. Chem. 15 : 2991-2999.
6. Kedzierska, K., and S. M. Crowe. 2001. Cytokines and HIV-1: interactions and clinical implications. Antivir. Chem. Chemother. 12 : 133-150.
7. Riddler, S. A., E. Smit, S. R. Cole, R. Li, J. S. Chmiel, A. Dobs, F. Palella, B. Visscher, R. Evans, and L. A. Kingsley. 2003. Impact of HIV infection and HAART on serum lipids in men. JAMA. 289 : 2978-2982.
8. Rose, H., I. Woolley, J. Hoy, A. Dart, B. Bryant, A. Mijch, and D. Sviridov. 2006. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 55 : 90-95.
9. Shor-Posner, G., A. Basit, Y. Lu, C. Cabrejos, J. Chang, M. Fletcher, E. Mantero-Atienza, and M. K. Baum. 1993. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am. J. Med. 94 : 515-519.
10. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am. J. Med. 62 : 707-714.
11. Michos, E. D., C. T. Sibley, J. T. Baer, M. J. Blaha, and R. S. Blumenthal. 2012. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J. Am. Coll. Cardiol. 59 : 2058-2064.
12. Hewing, B., K. J. Moore, and E. A. Fisher. 2012. HDL and cardiovascular risk: time to call the plumber? Circ. Res. 111 : 1117-1120.
13. Camont, L., M. J. Chapman, and A. Kontush. 2011. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17 : 594-603.
14. Florentin, M., E. N. Liberopoulos, A. S. Wierzbicki, and D. P. Mikhailidis. 2008. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 23 : 370-378.
15. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364 : 127-135.
16. Rose, H., J. Hoy, I. Woolley, U. Tchoua, M. Bukrinsky, A. Dart, and D. Sviridov. 2008. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 199 : 79-86.
17. Rose, H., H. Low, E. Dewar, M. Bukrinsky, J. Hoy, A. Dart, and D. Sviridov. 2013. The effect of HIV infection on atherosclerosis and lipoprotein metabolism: a one year prospective study. Atherosclerosis. 229 : 206-211.
18. Larrede, S., C. M. Quinn, W. Jessup, E. Frisdal, M. Olivier, V. Hsieh, M. J. Kim, M. Van. Eck, P. Couvert, A. Carrie, et al. 2009. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29 : 1930-1936.
19. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat. 2007. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48 : 2453-2462.
20. Jessup, W., I. C. Gelissen, K. Gaus, and L. Kritharides. 2006. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17 : 247-257.
21. Vergeer, M., S. J. Korporaal, R. Franssen, I. Meurs, R. Out, G. K. Hovingh, M. Hoekstra, J. A. Sierts, G. M. Dallinga-Thie, M. M. Motazacker, et al. 2011. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364 : 136-145.
22. Wang, N., D. Lan, W. Chen, F. Matsuura, and A. R. Tall. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA. 101 : 9774-9779.
23. Charles-Schoeman, C., Y. Y. Lee, V. Grijalva, S. Amjadi, J. FitzGerald, V. K. Ranganath, M. Taylor, M. McMahon, H. E. Paulus, and S. T. Reddy. 2012. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 71 : 1157-1162.
24. McGillicuddy, F. C., M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly. 2009. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 119 : 1135-1145.
25. Guérin, M., P. J. Dolphin, and M. J. Chapman. 1994. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler. Thromb. 14 : 199-206.
26. Guerin, M., T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman. 2000. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20 : 189-197.
27. Villard, E. F., P. El Khoury, E. Duchene, D. Bonnefont-Rousselot, K. Clement, E. Bruckert, R. Bittar, W. Le Goff, and M. Guerin. 2012. Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women. Arterioscler. Thromb. Vasc. Biol. 32 : 2341-2349.
28. Villard, E. F., M. C. Federspiel, C. Cherfils, V. Fesel-Fouquier, E. Bruckert, K. Clement, D. Bonnefont-Rousselot, W. Le Goff, R. Bittar, P. Couvert, et al. 2013. Endogenous CETP activity as a predictor of cardiovascular risk: determination of the optimal range. Atherosclerosis. 227 : 165-171.
29. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold. 1992. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74 : 1045-1052.
30. Hoang, A., B. G. Drew, H. Low, A. T. Remaley, P. Nestel, B. A. Kingwell, and D. Sviridov. 2012. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J. 33 : 657-665.
31. Mujawar, Z., H. Rose, M. P. Morrow, T. Pushkarsky, L. Dubrovsky, N. Mukhamedova, Y. Fu, A. Dart, J. M. Orenstein, Y. V. Bobryshev, et al. 2006. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 4 : e365.
32. Aragonés, G., R. Beltrán-Debón, A. Rull, F. Rodríguez-Sanabria, L. Fernández-Sender, J. Camps, J. Joven, and C. Alonso-Villaverde. 2010. Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Clin. Chem. Lab. Med. 48 : 1147-1152.
33. Riddler, S. A., X. Li, J. Otvos, W. Post, F. Palella, L. Kingsley, B. Visscher, L. P. Jacobson, and A. R. Sharrett. 2008. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 48 : 281-288.
34. Tien, P. C., M. F. Schneider, C. Cox, M. Cohen, R. Karim, J. Lazar, M. Young, and M. J. Glesby. 2010. HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study. AIDS. 24 : 2809-2817.
35. Duprez, D. A., L. H. Kuller, R. Tracy, J. Otvos, D. A. Cooper, J. Hoy, J. Neuhaus, N. I. Paton, N. Friis-Moller, F. Lampe, et al. 2009. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 207 : 524-529.
36. Lampe, F. C., D. A. Duprez, L. H. Kuller, R. Tracy, J. Otvos, E. Stroes, D. A. Cooper, J. Hoy, N. I. Paton, N. Friis-Moller, et al. 2010. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 54 : 275-284.
37. Oram, J. F., and A. M. Vaughan. 2000. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 11 : 253-260.
38. Remaley, A. T., U. K. Schumacher, J. A. Stonik, B. D. Farsi, H. Nazih, and H. B. Brewer, Jr. 1997. Decreased reverse cholesterol transport from Tangier disease fibroblasts. Acceptor specificity and effect of brefeldin on lipid efflux. Arterioscler. Thromb. Vasc. Biol. 17 : 1813-1821.
39. Out, R., W. Jessup, W. Le Goff, M. Hoekstra, I. C. Gelissen, Y. Zhao, L. Kritharides, G. Chimini, J. Kuiper, M. J. Chapman, et al. 2008. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ. Res. 102 : 113-120.
40. Ripollés Piquer, B., H. Nazih, A. Bourreille, J. P. Segain, J. M. Huvelin, J. P. Galmiche, and J. M. Bard. 2006. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 55 : 980-988.
41. Tréguier, M., M. Moreau, A. Sposito, M. J. Chapman, and T. Huby. 2007. LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI/Cla-1 receptor. Biochim. Biophys. Acta. 1771 : 129-138.
42. Weibel, G. L., D. Drazul-Schrader, D. K. Shivers, A. N. Wade, G. H. Rothblat, M. P. Reilly, and M. de la Llera-Moya. 2014. Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 34 : 17-25.
43. Catalano, G., Z. Julia, E. Frisdal, B. Vedie, N. Fournier, W. Le Goff, M. J. Chapman, and M. Guerin. 2009. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler. Thromb. Vasc. Biol. 29 : 268-275.
44. Gelissen, I. C., M. Harris, K. A. Rye, C. Quinn, A. J. Brown, M. Kockx, S. Cartland, M. Packianathan, L. Kritharides, and W. Jessup. 2006. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 26 : 534-540.
45. Rothblat, G. H., and M. C. Phillips. 1982. Mechanism of cholesterol efflux from cells. Effects of acceptor structure and concentration. J. Biol. Chem. 257 : 4775-4782.
46. Wang, N., M. Ranalletta, F. Matsuura, F. Peng, and A. R. Tall. 2006. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 26 : 1310-1316.
47. Fournier, N., O. Francone, G. Rothblat, D. Goudouneche, M. Cambillau, G. Kellner-Weibel, P. Robinet, L. Royer, N. Moatti, A. Simon, et al. 2003. Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis. 171 : 287-293.
48. Diditchenko, S., A. Gille, I. Pragst, D. Stadler, M. Waelchli, R. Hamilton, A. Leis, and S. D. Wright. 2013. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33 : 2202-2211.
49. Haase, C. L., A. Tybjaerg-Hansen, P. Grande, and R. Frikke-Schmidt. 2010. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J. Clin. Endocrinol. Metab. 95 : E500-E510.
50. Waksman, R., R. Torguson, K. M. Kent, A. D. Pichard, W. O. Suddath, L. F. Satler, B. D. Martin, T. J. Perlman, J. A. Maltais, N. J. Weissman, et al. 2010. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 55 : 2727-2735.